Abivax isn't fielding acquisition offers just yet. CEO Marc de Garidel told CNBC the French biotech firm will wait for key clinical trial results in June before negotiating partnerships, signaling confidence in their internal data. The company's stock surged 1,700% in 2025, driven by early signals from their lead asset, obefazimod.

The upcoming maintenance trial readout acts as a critical validation gate. If positive, Abivax plans to seek FDA approval by Q4 2026 and raise capital through equity or debt to reach profitability. De Garidel noted that waiting improves leverage: "The terms are going to be better... since we're confident that this study is going to read positively." Why hurry when the readout is only three months away?

Financially, the company holds 530 million euros, sufficient until late 2027. R&D expenses climbed to 177.8 million euros in 2025 as they prepared for commercialization. However, scaling globally remains a challenge for a team of 150. They intend to partner for non-U.S. launches post-data, though external variables complicate the strategy. President Trump's renewed Most Favored Nation pricing policy creates uncertainty, requiring any international partner to ensure overseas pricing doesn't undercut U.S. valuations.

Analysts remain split on the optimal exit timing. Some expect a pre-data acquisition given the asset's scarcity in the ulcerative colitis market, while others agree holding out maximizes value. Meanwhile, Abivax is bolstering its commercial team, hiring former Takeda VP Michael Nesrallah. For now, the message to potential buyers is clear: wait for the numbers. The company treats the June data as the inflection point that dictates their next architectural move, whether that means going solo or integrating with a larger pharma entity.

Source: CNBC